The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

In a recent study posted to the bioRxiv* preprint server, researchers investigated whether immunity against seasonal human coronavirus (CoV) spike (S) proteins of HKU1, OC43, NL63, or 229E could protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro. They also investigated the impact of pre-existing immune levels against seasonal CoV S on the immune protection conferred by messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccinations.

Study: Immunity to seasonal coronavirus spike proteins does not protect from SARS-CoV-2 challenge in a mouse model but has no detrimental effect on protection mediated by COVID-19 mRNA vaccination. Image Credit: JIMMOYHT/Shutterstock
Study: Immunity to seasonal coronavirus spike proteins does not protect from SARS-CoV-2 challenge in a mouse model but has no detrimental effect on protection mediated by COVID-19 mRNA vaccination. Image Credit: JIMMOYHT/Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Background

Seasonal CoVs have widely circulated among humans for several years. With advancing age, the likelihood of viral exposures and the generation of immunity against them increases. Researchers have hypothesized that anti-seasonal CoV immunity could partially protect against COVID-19 and that SARS-CoV-2 vaccinations induce back-boosting effects against the seasonal β-CoV S proteins. However, the effects of anti-seasonal CoV immunity on SARS-CoV-2 infection susceptibility and COVID-19 mRNA vaccinations are unclear.

About the study

In the present study, researchers evaluated the immune protective effects of anti-seasonal CoV S immunity against COVID-19-causing SARS-CoV-2 in mice and whether the pre-existing immune levels to seasonal CoVs impacted the immune protection conferred by SARS-CoV-2 vaccinations.

Mice were vaccinated with NL63, 229E, OC43, HKU1, and SARS-CoV-2 S proteins in prime-boost regimens. For comparison, control mice received influenza-causing virus HA (hemagglutinin) antigen vaccinations. After 28 days of booster vaccinations, immunological responses among the animals were measured using enzyme-linked immunosorbent assays (ELISA).

In addition, mice sera were assessed by ADCC (antibody-dependent cellular cytotoxicity) reporter assays. After 21 days of booster vaccinations, mice were intranasally transduced with non-replicating adenovirus-expressing hACE2 (human angiotensin-converting enzyme 2) followed by SARS-CoV-2 wild-type (wt) Washington-1 strain challenge after five days.

Mice were euthanized after three days and five days of SARS-CoV-2 to obtain their pulmonary tissues for viral load quantification by classic plaque assays, and their antibody titers were determined. Further, mice were vaccinated 21 days post-boost with a SARS-CoV-2 S-encoded LNP (lipid nanoparticle)-formulated and nucleoside-modified mRNA vaccine encoding the SARS-CoV-2 S. An unvaccinated control group was added for comparative evaluation. Vero E6 cells were used for cell culture experiments, and neutralization assays were performed.

Results

Seasonal CoV S induced robust and targeted immunological responses among the animals with considerable alpha-CoV and beta-CoV cross-reactivity. Pre-existing seasonal CoV S immunity provided negligible immune protection against SARS-CoV-2 but did not show any negative effects on vaccination-induced anti-SARS-CoV-2 immunity.

229E S-vaccinated mice sera reacted robustly with 229E S, whereas activity against NL63 S was lowered, and no activity was observed among the three beta-CoV S. NL63 S appeared to be marginally less immunogenic and generated comparable titers indicating strong activity against the homologous S, lesser reactivity to 229E S and some, although lowered reactivity to β-CoV S.

OC43 vaccination induced robust anti-OC43 S activity, lower activity for HKU-1 S and SARS-CoV-2, and negligible activity for α-CoVs. HKU1 S vaccination led to strong activity for the homologous S and lesser titers for SARS-CoV-2 S and OC43. SARS-CoV-2 S vaccination induced high reactivity for the homologous S with little cross-reactivity for HKU-1 and OC43 but no α-CoV S reactivity. SARS-CoV-2 S-vaccinated mice were the only animals that showed protection from the viral challenge.

High SARS-CoV-2 S levels were observed among all the seasonal coronaviruses’ S-vaccinated animals at comparable levels as in controls. No mice exhibited overt illness after challenge, and serological titers against SARS-CoV-2 S titers among all the seasonal coronavirus S-vaccinated animals were significantly elevated with a similar elevation among controls.

SARS-CoV-2 S-vaccinated mice titers did not show any increases after infection, indicative of sterilizing immune responses, and negligible back-boosting to seasonal CoV S was observed. The vaccination led to high neutralization and binding antibody titers against the S proteins of SARS-CoV-2 among all the groups, with the greatest titers among SARS-CoV-2 S-vaccinated animals and lesser titers among those vaccinated with HA or seasonal CoV S.

The similarity in titers among mice vaccinated with the S proteins of seasonal coronaviruses and HA antigens of the influenza virus indicated no detrimental effects on immunological responses to SARS-CoV-2 mRNA-LNP vaccines. No viral organisms were detected in mRNA-LNP-immunized mice on the third day or fifth-day post-challenge; however, increased titers were observed among completely naïve mice. The findings indicated that a fraction of SARS-CoV-2 S-vaccinated mice were active against cellular surface-expressed S proteins. However, serum samples of seasonal CoV S-vaccinated animals did not show activity except for two HKU1 responders.

Conclusion

Overall, the study findings showed that seasonal CoV S-vaccinated mice S proteins did not exhibit any added immune protection compared to controls against SARS-CoV-2. A negligible back-boosting effect was observed against β-CoV S post-SARS-CoV-2 infection; however, no negative original antigenic sin-like effects were observed on the SARS-CoV-2 mRNA vaccination-induced immunological responses among mice with pre-existing anti-seasonal CoV S immunity.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:
  • Preliminary scientific report. Amanat, F. et al. (2022) "Immunity to seasonal coronavirus spike proteins does not protect from SARS-CoV-2 challenge in a mouse model but has no detrimental effect on protection mediated by COVID-19 mRNA vaccination". bioRxiv. doi: 10.1101/2022.10.25.513804https://www.biorxiv.org/content/10.1101/2022.10.25.513804v1
  • Peer reviewed and published scientific report. Amanat, Fatima, Jordan Clark, Juan Manuel Carreño, Shirin Strohmeier, Temima Yellin, Philip S. Meade, Disha Bhavsar, et al. 2023. “Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 MRNA Vaccination.” Edited by Mark T. Heise. Journal of Virology 97 (3). https://doi.org/10.1128/jvi.01664-22. https://journals.asm.org/doi/10.1128/jvi.01664-22.

Article Revisions

  • May 15 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Pooja Toshniwal Paharia

Written by

Pooja Toshniwal Paharia

Pooja Toshniwal Paharia is an oral and maxillofacial physician and radiologist based in Pune, India. Her academic background is in Oral Medicine and Radiology. She has extensive experience in research and evidence-based clinical-radiological diagnosis and management of oral lesions and conditions and associated maxillofacial disorders.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Toshniwal Paharia, Pooja Toshniwal Paharia. (2023, May 15). The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination. News-Medical. Retrieved on October 11, 2024 from https://www.news-medical.net/news/20221028/The-impact-of-seasonal-coronavirus-immunity-on-susceptibility-to-SARS-CoV-2-infection-and-COVID-19-vaccination.aspx.

  • MLA

    Toshniwal Paharia, Pooja Toshniwal Paharia. "The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination". News-Medical. 11 October 2024. <https://www.news-medical.net/news/20221028/The-impact-of-seasonal-coronavirus-immunity-on-susceptibility-to-SARS-CoV-2-infection-and-COVID-19-vaccination.aspx>.

  • Chicago

    Toshniwal Paharia, Pooja Toshniwal Paharia. "The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination". News-Medical. https://www.news-medical.net/news/20221028/The-impact-of-seasonal-coronavirus-immunity-on-susceptibility-to-SARS-CoV-2-infection-and-COVID-19-vaccination.aspx. (accessed October 11, 2024).

  • Harvard

    Toshniwal Paharia, Pooja Toshniwal Paharia. 2023. The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination. News-Medical, viewed 11 October 2024, https://www.news-medical.net/news/20221028/The-impact-of-seasonal-coronavirus-immunity-on-susceptibility-to-SARS-CoV-2-infection-and-COVID-19-vaccination.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Long COVID affects 38% of emergency patients with persistent symptoms